Federal health officials just froze new enrollments for key medical supply companies, a move they say will stop Medicare fraud and save taxpayers millions while critics warn it could also block honest providers.
Story Snapshot
- CMS ordered a six‑month nationwide halt on new Medicare enrollment for seven types of durable medical equipment medical supply companies, with power to extend it.
- The moratorium targets suppliers CMS says carry a high risk of fraud, waste, and abuse, while allowing existing companies to keep serving patients.
- The freeze also stops certain ownership changes that would trigger new enrollment, shaking up mergers and business sales in the healthcare supply market.
- Industry groups and critics argue the broad crackdown will block legitimate new practices, raising fears of government overreach and fewer choices for patients.
Trump‑Era Medicare Fraud Crackdown Hits Medical Supply Firms
The Centers for Medicare and Medicaid Services, now led by Administrator Dr. Mehmet Oz, has launched a major fraud crackdown by blocking new Medicare enrollment for select durable medical equipment medical supply companies for six months. The order applies nationwide and covers businesses whose main job is to provide home medical supplies and equipment to patients or providers. The Trump administration is framing this as a “detect and prevent” push to keep crooked companies out of the system before they can bill taxpayers.
According to the official Federal Register notice, the moratorium took legal effect on February 27, 2026, and will run for six months. Separate guidance shows CMS first announced the move on February 25, and some accreditation bodies are treating that as the practical start date for deciding which applications are grandfathered. That small date gap matters because any enrollment forms reaching the contractor after the effective date must be denied under the new rules.
Seven High‑Risk Supplier Types Put On Hold
CMS singled out seven specific “medical supply company” categories it believes carry a high risk of fraud, waste, or abuse. These include plain medical supply companies and those that employ orthotics, pedorthic, prosthetics, prosthetic and orthotic, pharmacist, or respiratory therapist personnel. For all seven, no new Medicare enrollment applications will be approved during the moratorium, and no new practice locations for these categories can join the program unless their paperwork was received before the cutoff date.
Federal guidance explains that a medical supply company is a business whose main function is furnishing durable medical equipment, prosthetics, orthotics, and supplies directly to patients or other providers. CMS argues these companies sit at a high‑risk choke point where dishonest actors can push unnecessary or fake claims through Medicare by shipping items that may never be needed or even used. By freezing new entries across these categories, CMS reduces the number of targets fraudsters can hide behind while the agency steps up data reviews and enforcement.
Existing Suppliers Protected While Ownership Deals Face New Scrutiny
The moratorium is carefully aimed at new enrollment, not at currently approved suppliers who keep their existing structure. Legal alerts note that present medical supply companies can still change basic details like addresses or phone numbers and continue billing Medicare as usual. This design protects continuity of care for seniors who rely on oxygen supplies, prosthetics, sleep therapy equipment, and other home devices, while focusing the crackdown on new businesses that have not yet proven they are honest operators.
At the same time, the moratorium reaches into ownership changes that trigger what CMS treats as a “new” enrollment. Under a 36‑month rule in federal regulations, a change in majority ownership often requires a fresh initial application. CMS has clarified that such change‑in‑majority‑ownership deals are now subject to the moratorium, meaning planned mergers, buyouts, or new locations in the seven categories can be blocked for the duration. That has already prompted warning memos to investors that compliance and timing are now critical for any deal touching these supplier types.
Authority to Extend, But Little Public Data Behind the Decision
CMS has the clear authority to extend this moratorium beyond the first six months, in additional six‑month blocks, if officials believe fraud risks remain high. The agency says it will review enrollment and claims data before each extension and will publish any decision to lift or continue the freeze in the Federal Register. For taxpayers worried about waste, this flexible power is meant to keep pressure on suspicious billing patterns until they are cleaned up or controlled.
The U.S. Centers for Medicare and Medicaid Services, led by Mehmet Oz, has regulatory power over California’s plan for the managed care tax.- https://t.co/AX4uUVJhi0
— CPA Practice Advisor (@cpapracadvisor) July 9, 2026
So far, however, CMS has not released a detailed public audit showing exactly how much fraud is tied to these seven supplier types, even though officials cite very large overall Medicare fraud estimates when defending the policy. Industry summaries note that similar moratoria have been used several times since 2009 when “anomalous” billing spikes appeared in the durable equipment sector. That history backs the idea that this crackdown fits a broader pattern of regulators using enrollment freezes as a blunt tool when they suspect trouble, even if the specific numbers are kept inside the agency.
Conservative Concerns: Stopping Scammers Without Crushing Honest Providers
For many conservative readers, the core tension is clear: Medicare fraud is real, ugly, and expensive, but broad federal freezes can also hurt honest small businesses and limit patient choice. Sleep practices planning new positive airway pressure services and prosthetics clinics looking to open new locations say this moratorium suddenly blocks them from serving Medicare patients, even though they have no history of fraud. Trade groups have already warned members to pick non‑blocked enrollment categories where possible, or delay expansion plans.
Critics on the left focus on Dr. Oz’s public comments about fraud and insurance use, calling his explanations confused and “terrifying,” yet they have not produced hard evidence disproving CMS’s claim that these supplier types pose higher risk. For conservatives, that leaves a mixed picture. On one hand, the Trump administration is finally putting serious teeth into stopping scam medical supply companies that bleed Medicare dry. On the other hand, the lack of transparent, detailed fraud data and the broad reach into legitimate new entrants fuel worries about government overreach and the need for tighter, more targeted reforms that punish criminals without trapping the innocent.
Sources:
thegatewaypundit.com, bakerdonelson.com, appliedpolicy.com, cms.gov, nixonpeabody.com, federalregister.gov
